Canada reviews diabetes drug

According to international diabetes news today, the Candian Health Ministry is reviewing the diabetes drug Lantus following claims of an increased risk of cancer. Lantus, marketed by pharmaceutical company Sanofi-Aventis, is sold worldwide in great volumes.
The CHM reportedly commented: “Health Canada is informing Canadians of an ongoing safety review of the potential association between the diabetes drug Lantus ( insulin glargine ) and an increased risk of developing cancer .”
However, the Food and Drug Administration in America cast doubt on the studies. Lantus is a synthetic insulin used to control blood sugar amongst people with type 1 diabetes and people with type 2 diabetes .
At this stage, the Canadian authority is advising people with diabetes to contact their healthcare professional if they have concerns about their medication .